Fennec Pharmaceuticals In... (FENC)
5.72
0.07 (1.24%)
At close: Apr 24, 2025, 12:14 PM
Company Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.
Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Sep 15, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Jeffrey S. Hackman |
Contact Details
Address: 68 TW Alexander Drive Research Triangle Park, North Carolina United States | |
| Website | https://www.fennecpharma.com |
Stock Details
| Ticker Symbol | FENC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001211583 |
| CUSIP Number | 31447P100 |
| ISIN Number | CA31447P1009 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey S. Hackman | Chief Executive Officer & Director |
| Robert C. Andrade | Chief Financial Officer |
| Christiana Cioffi M.B.A. | Chief Strategy Officer |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer |
| Lei Fang | President of Pharstat Inc |
| Mark Gowland | Controller |
| Terry Evans | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 04, 2025 | 4 | Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 01, 2025 | 4 | Filing |